Navigation Links
Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug
Date:3/20/2012

gs, many of which have significant side effects. The potential market for XEN-D0103 is significant with one in four adults over the age of 40 developing AF in their lifetimes and approximately three million patients suffering atrial-fibrillation-related strokes each year. We are now preparing for the initiation of phase 2 efficacy trial of XEN-D0103 in patients with atrial fibrillation".

XEN-D0103 is the lead product of Xention's portfolio of atrial fibrillation drugs. In addition to targeting Kv1.5, Xention is also conducting research on inhibition of the acetylcholine-activated potassium channel IKACh (Kir3.1/3.4) and highly potent and selective IKACh antagonists are currently under evaluation in preclinical models. The ion channels Kv1.5 and IKACh represent two of the most exciting targets for novel atrial fibrillation therapies, and Xention is at the forefront in developing effective drug modulators of these channels.

About Atrial Fibrillation:

Atrial Fibrillation (AF) is the most common sustained cardiac rhythm disturbance, occurring in between 1 and 2 per cent of the general population but increasing rapidly with age.  It is estimated that over six million Europeans suffer from this arrhythmia and its prevalence is calculated to increase by at least 2.5 fold in the next 50 years as the population ages.  AF confers a five-fold increased risk of stroke and one in five of all strokes are attributable to AF.  The ischemic strokes seen in association with the arrhythmia are often fatal, and those that survive are often left crippled by their stroke and likely to suffer recurrent strokes.  Around one per cent of the healthcare budget of Western European and North American countries is spent on the management of AF.  Thus this disease presents a rapidly growing social, medical and public health problem in need of urgent solution.

Notes to Editors

About Xention:

Xention Ltd is a leading d
'/>"/>

SOURCE Xention
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GenVec Reports Fourth Quarter and 2011 Year-End Financial Results
2. EntreMed Reports Fourth Quarter and Year-End 2011 Financial Results
3. Phalanx Biotech Group Reports Robust Revenue Growth in 2011
4. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
5. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
6. Gen-Probe Reports Financial Results for the Fourth Quarter of 2011
7. Neuland Labs Reports Third Quarter Fiscal Year 2012 Financial Results
8. Cepheid Reports Fourth Quarter and Full Year 2011 Results
9. Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M
10. Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012
11. Idenix Reports Positive Interim Data for HCV Nucleotide Inhibitor, IDX184
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2015)... 29, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") today ... 2014. Biorem,s complete fiscal 2014 year-end financial statements and MD&A have been ... , 2013 , 2014 , 2013 Revenue ... 19,596 Gross profit 1,326 , 1,703 , 2,231 ... 1,493 , 3,377 , 4,562 Ebitda* 92 ...
(Date:4/29/2015)... 2015 Cambrex Corporation (NYSE: CBM ) announced ... Friday, May 1, 2015 before the market opens. , ... host a conference call to discuss the financial results. First ... , Friday, May 1, 2015 at 8:30 a.m. Eastern ... U.S.1-719-325-2454 for International  Passcode:  7993632 Dial-in Replay: ...
(Date:4/29/2015)... The leading Regenerative Veterinary Medicine Company, VetStem ... cell therapy has processed more than 11,000 samples. ... successful treatment for horses with potentially fatal injuries to ... worldwide exclusive license for adipose-derived (fat derived) stem cell ... treated in January 2004. Shortly after, the first dogs ...
(Date:4/29/2015)... - Northern Biologics Inc., a privately held biotechnology company ... strategic collaboration with Celgene Corporation.  As part of ... upfront cash payment. It will use the funds ... will have the right to receive additional future ... Under the agreement, Northern Biologics ...
Breaking Biology Technology:Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples 2Northern Biologics and Celgene Enter Strategic Collaboration 2
... predicting and quashing environmental decoherence, a phenomenon that has proven ... the way of quantum computing. The findings based ... and confirmed by experiments at the University of California Santa ... of the journal Nature . Quantum mechanics states ...
... July 20, 2011 Regulus Therapeutics Inc ., ... innovative medicines targeting microRNAs, today announced that it has ... GlaxoSmithKline (GSK), triggering a preclinical milestone payment from GSK. ... its microRNA alliance with GSK, which is focused on ...
... July 20, 2011 ReSearch Pharmaceutical Services, Inc. ... global Phase II-IV clinical development solutions to the ... following key additions to its Operational and Senior ... Davis, II, as Chief Information Officer and Executive ...
Cached Biology Technology:Discovery may overcome obstacle for quantum computing 2Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 2Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 3Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 4RPS Continues Expansion of Global Clinical, Regulatory, Medical, and Operational Leadership 2RPS Continues Expansion of Global Clinical, Regulatory, Medical, and Operational Leadership 3
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:4/2/2015)... Germany , April 2, 2015 ... fingerprint tests DERMALOG by far outperforms the strongest ... always maintaining high accuracy, the system is capable ... Hence, the speed proves up to be ten ... faster than its runner-up performance.      ...
(Date:4/2/2015)... Fingerprint Cards (FPC) has received ... the distributor World Peace Industrial Group (WPI), part of ... the major part of the shipments will take place ... smartphone manufacturers in China . The ... communicated revenue guidance of + 1 000 MSEK for 2015.  ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... 26, 2011Magnetic resonance tractography (MRT) is a valuable, ... and, as MRT methods and technologies advance, has ... on brain activity and connectivity. Critical information about ... explored in a forward-looking review article in the ...
... Texas at Austin researchers have discovered how to extract and ... objects are from the focus distance, a feat only accomplished ... Like a camera, the human eye has an auto-focusing system, ... humans do not require trial and error to focus an ...
... used local anesthetic, may more easily wiggle into a ... compounds that carry a negative charge, a new study ... more complete understanding of the molecular-level mechanisms behind pain-blocking ... use. Most scientists believe that local anesthetics prevent ...
Cached Biology News:Researchers develop optimal algorithm for determining focus error in eyes and cameras 2
L1 Protein of Human Papilloma Virus Purified Anti-Viral-transformed cells clone CAMVIR-1, Isotype Mouse IgG 2a , 0.1 mg Consult technical datasheet for details....
ANTI 5-HYDROXYTRYPTOPHAN CONJ....
PAb to Hu-IFN-Alpha/Beta R2 [(IFNAR2) CD118], Rabbit Serum, neutralizing Binds to but does not neutralize human interferon alpha/beta receptor...
IMAGEQUANT 100 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
Biology Products: